Detalles de la búsqueda
1.
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
Eur J Cancer
; 201: 113589, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38382153
2.
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
Eur Urol Oncol
; 2023 Oct 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37813745
3.
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
Eur J Cancer
; 182: 66-76, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36746010
4.
Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group.
Crit Rev Oncol Hematol
; 173: 103661, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35341986
5.
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Clin Genitourin Cancer
; 20(5): 488-494, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35977881
6.
Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.
J Immunother Cancer
; 10(5)2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35640928
7.
Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.
Eur Urol
; 80(3): 325-329, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34103181
8.
Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.
Front Oncol
; 9: 1033, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31649889
9.
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
J Clin Oncol
; 37(23): 2008-2016, 2019 08 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31194611
Resultados
1 -
9
de 9
1
Próxima >
>>